Literature DB >> 16603184

Blockade of histamine H2 receptors protects the heart against ischemia and reperfusion injury in dogs.

Hiroshi Asanuma1, Tetsuo Minamino, Akiko Ogai, Jiyoong Kim, Masanori Asakura, Kazuo Komamura, Shoji Sanada, Masashi Fujita, Akio Hirata, Masakatsu Wakeno, Osamu Tsukamoto, Yoshiro Shinozaki, Masafumi Myoishi, Seiji Takashima, Hitonobu Tomoike, Masafumi Kitakaze.   

Abstract

We have previously reported that histamine H(2) blockers may be cardioprotective in patients with chronic heart failure. Since both endogenous histamine and histamine H(2) receptors are present in heart tissue, we tested the hypothesis that the blockade of histamine H(2) receptors mediates protection against reversible or irreversible ischemia and reperfusion injury. In open-chest dogs, the left anterior descending coronary artery was occluded for 90 minutes, followed by reperfusion for 6 hours. Administration of famotidine and cimetidine from 10 minutes before occlusion until after 1 hour of reperfusion reduced infarct size (17.0 +/- 4.1% and 17.8 +/- 2.9% vs. 36.9 +/- 5.9% of the solvent group, respectively) Famotidine administration only during the reperfusion period for 1 hour also attenuated infarct size (22.5 +/- 3.5%). There were no differences in either area at risk or collateral flow among the groups. In another set of experiments, we decreased coronary perfusion pressure in dogs so that the coronary blood flow decreased to 50% of the non-ischemic level. In such conditions, we observed the increases in histamine release compared with non-ischemic conditions (0.04 +/- 0.03 to 0.28 +/- 0.13 ng/ml, p < 0.05). Famotidine improved anaerobic myocardial metabolism gauged by both lactate extraction ratio and myocardial oxygen consumption. We conclude that the blockade of histamine H(2) receptors mediates improvements in the anaerobic myocardial metabolism, and thus protects against ischemia and reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16603184     DOI: 10.1016/j.yjmcc.2006.02.001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

Review 1.  Cardiac mast cells: the centrepiece in adverse myocardial remodelling.

Authors:  Scott P Levick; Giselle C Meléndez; Eric Plante; Jennifer L McLarty; Gregory L Brower; Joseph S Janicki
Journal:  Cardiovasc Res       Date:  2010-08-24       Impact factor: 10.787

2.  Arrhythmogenic effect of sympathetic histamine in mouse hearts subjected to acute ischemia.

Authors:  Gonghao He; Jing Hu; Teng Li; Xue Ma; Jingru Meng; Min Jia; Jun Lu; Hiroshi Ohtsu; Zhong Chen; Xiaoxing Luo
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

3.  The emerging prominence of the cardiac mast cell as a potent mediator of adverse myocardial remodeling.

Authors:  Joseph S Janicki; Gregory L Brower; Scott P Levick
Journal:  Methods Mol Biol       Date:  2015

Review 4.  The Roles of Cardiovascular H2-Histamine Receptors Under Normal and Pathophysiological Conditions.

Authors:  Joachim Neumann; Uwe Kirchhefer; Stefan Dhein; Britt Hofmann; Ulrich Gergs
Journal:  Front Pharmacol       Date:  2021-12-20       Impact factor: 5.810

Review 5.  Histamine receptors in heart failure.

Authors:  Scott P Levick
Journal:  Heart Fail Rev       Date:  2021-10-08       Impact factor: 4.654

6.  Glucagon effects on ischemic vasodilatation in the isolated rat heart.

Authors:  Mirko Rosic; Suzana Pantovic; Gvozden Rosic; Aleksandra Tomic-Lucic; Tatjana Labudovic; Vladimir Zivkovic; Vladimir Jakovljevic
Journal:  J Biomed Biotechnol       Date:  2010-03-18

7.  Histamine blood concentration in ischemic heart disease patients.

Authors:  Vladimir Zdravkovic; Suzana Pantovic; Gvozden Rosic; Aleksandra Tomic-Lucic; Nemanja Zdravkovic; Maja Colic; Zdravko Obradovic; Mirko Rosic
Journal:  J Biomed Biotechnol       Date:  2011-06-06

Review 8.  Mast Cells: Key Contributors to Cardiac Fibrosis.

Authors:  Scott P Levick; Alexander Widiapradja
Journal:  Int J Mol Sci       Date:  2018-01-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.